Core Viewpoint - The current diagnosis rate for chronic hepatitis B in China is approximately 22%, and the treatment rate is about 15%, indicating a significant gap compared to the targets set in the "Action Plan for the Prevention and Control of Viral Hepatitis (2025-2030)" which aims for an 80% diagnosis and treatment rate by 2030 [1] Group 1 - The integration of the "screen-diagnose-treat" system is expected to significantly improve the management coverage and accessibility of treatment for chronic hepatitis B patients [1] - The advancement in this integrated system is anticipated to have a positive impact on the hepatitis B drug market [1]

Group 1 - The company holds a 0.75% stake in Replicor through its wholly-owned subsidiary, Laimei Hong Kong [2] - Replicor's hepatitis B drug development project is progressing steadily, and the company will closely monitor the project's subsequent developments [2] - The company will fulfill its information disclosure obligations in accordance with relevant regulations from the Shenzhen Stock Exchange [2]